<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36786138</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-6360</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>05</Day></PubDate></JournalIssue><Title>Current rheumatology reviews</Title><ISOAbbreviation>Curr Rheumatol Rev</ISOAbbreviation></Journal><ArticleTitle>Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as the Future of Systemic Lupus Erythematosus Treatment.</ArticleTitle><Pagination><StartPage>260</StartPage><EndPage>269</EndPage><MedlinePgn>260-269</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/1573397119666230214103044</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is a chronic autoimmune illness with an unclear etiology and a range of clinical manifestations. The therapeutic results of current conventional treatments are frequently unsatisfactory. Many B-cell-directed immunotherapies have recently been discovered, as B cells play a key role in the pathogenesis of SLE. However, large-scale rituximab trials found that the antibody against CD20 was no better than a placebo. Autologous CAR T-cell therapy has garnered considerable interest and is considered a potential treatment option for SLE. CD19+CD20- B cells are thought to play an essential role in the onset and progression of SLE. CD19-targeted CAR T-cells destroy B cells without requiring an accessory cell type, thereby decreasing B cells more efficiently. Preclinical trials of CAR T-cells in mice have shown promising results against SLE. The review aimed to shed light on autologous CD19-targeted CAR T-cells as a potential treatment for SLE.</AbstractText><CopyrightInformation>Copyright&#xa9; Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kambayana</LastName><ForeName>Gede</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Udayana University / Prof dr I Goesti Ngoerah Gde Ngoerah General Hospital, Denpasar, Bali, Indonesia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Surya Rini</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, North Lombok Regional Hospital, West Nusa Tenggara, Indonesia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>Curr Rheumatol Rev</MedlineTA><NlmUniqueID>101261938</NlmUniqueID><ISSNLinking>1573-3971</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000076962">Receptors, Chimeric Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018941">Antigens, CD19</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000076962" MajorTopicYN="Y">Receptors, Chimeric Antigen</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001402" MajorTopicYN="N">B-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018941" MajorTopicYN="N">Antigens, CD19</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">B-cell</Keyword><Keyword MajorTopicYN="N">CAR T-cell therapy</Keyword><Keyword MajorTopicYN="N">CD19</Keyword><Keyword MajorTopicYN="N">potential</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">targeted.</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>14</Day><Hour>4</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36786138</ArticleId><ArticleId IdType="doi">10.2174/1573397119666230214103044</ArticleId><ArticleId IdType="pii">CRR-EPUB-129497</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>